Research Topics
Genomes and GenesSpecies | Bruce G PollockSummaryAffiliation: Rotman Research Institute Country: Canada Publications
| Collaborators
|
Detail Information
Publications
A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementiaBruce G Pollock
Rotman Research Institute at Baycrest, Toronto, Ontario, Canada
Am J Geriatr Psychiatry 15:942-52. 2007..To compare citalopram and risperidone for the treatment of psychotic symptoms and agitation associated with dementia, with a priori hypotheses that risperidone would be more efficacious for psychosis and citalopram for agitation...
D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophreniaHiroyuki Uchida
PET Centre, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
J Clin Psychopharmacol 29:571-5. 2009....- Cholinergic pathways and cognition in patients with schizophrenia: a pilot studyTarek K Rajji
Geriatric Mental Health Program, Centre for Addiction and Mental Health, Toronto, Canada
Schizophr Res 139:46-52. 2012..The objective of this study was to evaluate the impact of compromised cholinergic pathways on executive versus non-executive cognitive functions of patients with schizophrenia... - Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophreniaZahinoor Ismail
Centre for Addiction and Mental Health, Geriatric Mental Health Program, Toronto, Ontario, Canada
Am J Geriatr Psychiatry 20:53-60. 2012..The objective of this study was to assess the magnitude and variability of plasma concentrations of clozapine and norclozapine across the lifespan in a real-world clinical setting... - Clozapine and global cognition in schizophreniaTarek K Rajji
Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Toronto, Canada
J Clin Psychopharmacol 30:431-6. 2010..The relative effect and exposure to CLZ and its major metabolite-N-desmethylclozapine (NDMC)-could explain these discrepancies... 
The ZNF804A gene: characterization of a novel neural risk mechanism for the major psychosesAristotle N Voineskos
Department of Psychiatry, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada
Neuropsychopharmacology 36:1871-8. 2011..Our findings link genetic, imaging, and cognitive susceptibility relevant to both schizophrenia and bipolar disorder...- Age-related decline in white matter tract integrity and cognitive performance: a DTI tractography and structural equation modeling studyAristotle N Voineskos
Geriatric Mental Health Program, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Neurobiol Aging 33:21-34. 2012..e., splenium) of the corpus callosum with memory and executive function. Our findings suggest that decline in the microstructural integrity of white matter fibers can account for cognitive decline in normal aging... - Transient insight induction with electroconvulsive therapy in a patient with refractory schizophrenia: a case report and systematic literature reviewPhilip Gerretsen
Multimodal Imaging Group, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada
J ECT 27:247-50. 2011.... - Effects of aging on 5-HT(2A) R binding: a HRRT PET study with and without partial volume correctionsHiroyuki Uchida
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Int J Geriatr Psychiatry 26:1300-8. 2011.... - Increased antipsychotic sensitivity in elderly patients: evidence and mechanismsHiroyuki Uchida
Centre for Addiction and Mental Health, Positron Emission Tomography Centre, Ontario, Canada
J Clin Psychiatry 70:397-405. 2009.... - A Comparison of the E-BEHAVE-AD, NBRS, and NPI in Quantifying Clinical Improvement in the Treatment of Agitation and Psychosis Associated With DementiaZahinoor Ismail
Centre for Addiction and Mental Health, Geriatric Mental Health Program, and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada
Am J Geriatr Psychiatry 21:78-87. 2013.... - Is desire for social relationships mediated by the serotonergic system in the prefrontal cortex? An [(18)F]setoperone PET studyPhilip Gerretsen
University of Toronto, Toronto, Canada
Soc Neurosci 5:375-83. 2010..501, p = .017). These correlations were corroborated by a voxel-wise analysis. These results suggest that the serotonergic system may have a regulatory effect on the OFC and ACC for establishing and maintaining social relationships... - Use of lithium in the treatment of bipolar disorder in late-lifeRamsey D'Souza
Division of Geriatric Psychiatry, University of Toronto, and Geriatric Mental Health Program, Centre for Addiction and Mental Health, 1001 Queen Street West, Toronto, Ontario M6J 1H4, Canada
Curr Psychiatry Rep 13:488-92. 2011..Careful monitoring and adjustment of lithium dosage is especially important in older adults to minimize the risk of toxicity... - Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanismsHiroyuki Uchida
Schizophrenia Research Group, PET Centre, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada
Am J Geriatr Psychiatry 17:255-63. 2009..The objective of this study was to examine whether this sensitivity is due to a central pharmacokinetic (i.e., higher occupancy for a given plasma level) or pharmacodynamic (i.e., greater functional effects for a given occupancy) effect... - Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adultsTiffany W Chow
The Rotman Research Institute of Baycrest Centre for Geriatric Care, Toronto, ON, Canada
BMC Med Imaging 9:12. 2009..Methods: Six healthy subjects (age range = 65-78 years) completed two [18F]-setoperone PET scans on two separate occasions 5-16 weeks apart... - Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic studyHiroyuki Uchida
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
Ther Drug Monit 34:182-7. 2012..Using population pharmacokinetic methods, the authors therefore sought to predict plasma concentrations of risperidone (RIS) plus 9-hydroxyrisperidone (9-OH-RIS) before a dosage change... - The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer diseaseAristotle N Voineskos
Department of Psychiatry, Geriatric Mental Health Program, Centre for Addiction and Mental Health, 250 College St, Toronto, Ontario, Canada M5T 1R8
Arch Gen Psychiatry 68:198-206. 2011..Imaging-genetics strategies may clarify the manner in which BDNF gene variation predicts the risk of AD via characterization of its effects on at-risk structures or neural networks susceptible in this disorder... - Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic studyWenzie Ng
Centre for Addiction and Mental Health, Geriatric Mental Health Program, Toronto, Ontario M5T 1R8, Canada
Ther Drug Monit 31:360-6. 2009..These findings may account for some of the variability in clozapine exposure and have important implications for individualized drug dosing and therapeutic drug monitoring... - An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTPErik M van Oosten
Department of Chemistry, University of Toronto, 80 St George Street, Toronto, Ontario, Canada M5S 3H6
Appl Radiat Isot 67:611-6. 2009..This methodology offers higher yields, faster synthesis times, an optimized precursor, and simpler automation than previously reported... - Adherence to escitalopram treatment in depression: a study of electronically compiled dosing histories in the 'Depression: the search for phenotypes' studyAlette M Wessels
Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
Int Clin Psychopharmacol 27:291-7. 2012..IPT+escitalopram. Early discontinuation of treatment and suboptimal daily execution of the prescribed regimen are the most common facets of poor adherence in this study population... - Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapineBenoit H Mulsant
Western Psychiatric Institute and Clinic, Department of Psychiatry, Division of Geriatric Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
J Clin Psychiatry 65:1708-14. 2004..Older individuals with dementia are highly sensitive to the effects of muscarinic receptor blockade... - Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled studyCarmen Andreescu
Western Psychiatric Institute and Clinic, 3811 O Hara Street, Room E 823, Pittsburgh, PA15213, USA
Br J Psychiatry 190:344-9. 2007..Comorbid anxiety is common in depressive disorders in both middle and late life, and it affects response to antidepressant treatment... - Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbancesRobert R Bies
Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
Am J Geriatr Pharmacother 3:87-91. 2005..This study was intended to compare the consistency of risperidone exposure in patients who have dementia and behavioral disturbances treated in a psychiatric hospital versus a community care setting... - Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trialEric J Lenze
Intervention Research Center for Late Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine and VA Healthcare System, PA, USA
Am J Psychiatry 162:146-50. 2005..Anxiety disorders are highly prevalent in elderly persons. However, to date, the efficacy of selective serotonin reuptake inhibitors (SSRIs) for the treatment of anxiety disorders in this age group has not been established... - Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trialSteven P Roose
New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
Am J Psychiatry 161:2050-9. 2004..This study determined the efficacy of antidepressant medication for the treatment of depression in the "old-old.".. - Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policyCarl Salzman
Department of Psychiatry, Harvard Medical School, Boston, Mass 02115, USA
J Clin Psychiatry 69:889-98. 2008..In 2005, the FDA issued a black box warning regarding increased risk of mortality associated with the use of atypical antipsychotic drugs in this patient population... - Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatmentStephen Blank
Intervention Research Center for Late-Life Mood Disorders, The Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
J Clin Psychiatry 67:468-72. 2006..CONCLUSIONS: In this 32-week study of citalopram for elderly persons with anxiety disorders, 60% responded. Those who received a full course of treatment experience significant improvements in quality of life and sleep quality... - Effects of nortriptyline and paroxetine on postural sway in depressed elderly patientsDavid C Mamo
Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA
Am J Geriatr Psychiatry 10:199-205. 2002..Further studies with other SSRIs are needed... - Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patientsBruce G Pollock
Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA
Am J Psychiatry 159:460-5. 2002.... - Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration samplingYan Feng
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, PA 15261, USA, and Rotman Research Institute, Baycrest Hospital, University of Toronto, Canada
Br J Clin Pharmacol 61:558-69. 2006..The data indicate that female and male subjects with different CYP2D6 polymorphisms have different elimination rates and therefore may need to be dosed differently based on metabolizer genotype... - Persistence of neuropsychologic deficits in the remitted state of late-life depressionRishi K Bhalla
Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Am J Geriatr Psychiatry 14:419-27. 2006..In addition, a substantial proportion of older depressed individuals who are cognitively intact when depressed are likely to be impaired one year later, although their depression has remitted... - A model of anticholinergic activity of atypical antipsychotic medicationsMarci L Chew
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA
Schizophr Res 88:63-72. 2006..CONCLUSIONS: Therapeutic doses of clozapine, olanzapine, and, to a lesser extent, quetiapine are associated with clinically relevant AA... - Lower central serotonergic responsivity is associated with preclinical carotid artery atherosclerosisMatthew F Muldoon
Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA 15260, USA
Stroke 38:2228-33. 2007..This investigation tested a hypothesized association between central serotonergic functioning and preclinical atherosclerosis... - Emergence, persistence, and resolution of suicidal ideation during treatment of depression in old ageKatalin Szanto
University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, Pennsylvania 15213, United States
J Affect Disord 98:153-61. 2007..To determine the rate and clinical correlates of emergent, persistent, and resolved suicidal ideation during treatment of major depression in the elderly... - Cardiovascular changes associated with venlafaxine in the treatment of late-life depressionEllyn M Johnson
Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Am J Geriatr Psychiatry 14:796-802. 2006..Systematic monitoring of cardiovascular parameters during treatment with venlafaxine-XR should be strongly recommended, especially in the elderly... - Paroxetine treatment of primary insomnia in older adultsCharles F Reynolds
Advanced Center for Interventions and Services Research for Late Life Mood Disorders ACISR LLMD and the John A Hartford Center of Excellence in Geriatric Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
Am J Geriatr Psychiatry 14:803-7. 2006..The goal of this study was to test the efficacy of paroxetine for primary insomnia in older adults... - Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapyAlexandre Y Dombrovski
Western Psychiatric Institute and Clinic, Department of Psychiatry, School of Medicine, University of Pittsburgh, Pennsylvania, USA
J Am Geriatr Soc 55:1325-32. 2007..To determine whether maintenance antidepressant pharmacotherapy and interpersonal psychotherapy sustain gains in health-related quality of life (HR-QOL) achieved during short-term treatment in older patients with depression... - Risk factors for falls during treatment of late-life depressionJin H Joo
Intervention Research Center for Late-Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA
J Clin Psychiatry 63:936-41. 2002..Additionally, augmenting paroxetine with bupropion may also increase the risk of falls, and this medication combination should be used with caution in elderly patients... - Sex, race, and smoking impact olanzapine exposureKristin L Bigos
Department of Pharmaceutical Sciences, University of Pittsburgh, School of Pharmacy, 805 Salk Hall, 3501 Terrace St, Pittsburgh, PA 15261, USA
J Clin Pharmacol 48:157-65. 2008..0001). Differences in olanzapine exposure due to sex, race, and smoking may account for some of the variability in response to olanzapine... - Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patientsFrancis E Lotrich
NIMH Advanced Center in Interventions and Services Research for Late Life Mood Disorders and the John A Hartford Foundation Center of Excellence in Geriatric Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
J Psychiatry Neurosci 33:123-30. 2008..To investigate whether variable antidepressant response may be influenced by an interaction between the serotonin transporter promoter polymorphism (5-HTTLPR) and antidepressant concentration... - Desvenlafaxine succinate for major depressive disorderBeth A Sproule
The Centre for Addiction and Mental Health, University of Toronto, Canada
Drugs Today (Barc) 44:475-87. 2008..The only identified potential advantage of desvenlafaxine over venlafaxine or other antidepressant agents at this time is the apparently reduced risk for pharmacokinetic drug interactions... - Decreasing pain and anxiety associated with patient-activated atrial shock: a placebo-controlled study of adjunctive sedation with oral triazolamTanya J Fabian
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA
J Cardiovasc Electrophysiol 17:391-5. 2006..The main objective of the present study was to determine whether triazolam improved patient perception of the shock experience or altered patient memory of shock discomfort relative to placebo... - What is the optimal duration of a short-term antidepressant trial when treating geriatric depression?Benoit H Mulsant
Advanced Center in Intervention and Services Research for Late Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
J Clin Psychopharmacol 26:113-20. 2006..To determine the optimal duration of an antidepressant trial in elderly patients, the authors examined the probability of eventually responding to treatment based on early improvement... - Paroxetine-induced hyponatremia in older adults: a 12-week prospective studyTanya J Fabian
Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA
Arch Intern Med 164:327-32. 2004.... - Serotonin modulation of cerebral glucose metabolism in normal agingSara Goldberg
Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, Glen Oaks, NY 11004, USA
Neurobiol Aging 25:167-74. 2004..These results suggest different compensatory processes in anterior compared to posterior brain regions secondary to the age-related loss of serotonin innervation... - Plasma levels of citalopram in depressed patients with hepatitis COndria C Gleason
Department of Psychiatry, University of Oklahoma College of Medicine Tulsa, 74135 2512, USA
Psychosomatics 45:29-33. 2004.... - alpha1-acid glycoprotein in late-life depression: relationship to medical burden and geneticsOpeolu M Adeoye
Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio, USA
J Geriatr Psychiatry Neurol 16:235-9. 2003..Frequency differences in ORM1 allelic variants apparently did not influence increased AAG concentrations in depressed patients... - Good treatment outcomes in late-life depression with comorbid anxietyEric J Lenze
The Intervention Research Center in Late Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
J Affect Disord 77:247-54. 2003..This study evaluated the impact of comorbid anxiety on response, dropouts, and side effects, in elderly subjects treated for depression... - Paroxetine-induced hyponatremia in the elderly due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)Tanya J Fabian
Intervention Research Center for Late Life Mood Disorders, USA
J Geriatr Psychiatry Neurol 16:160-4. 2003..Data suggest hyponatremia is a common adverse event in elderly patients prescribed paroxetine and implicates inappropriate secretion of ADH as the potential mechanism... - Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depressionGwenn S Smith
Department of Psychiatry Research, Hillside Hospital and the Neuroscience Institute of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
Am J Geriatr Psychiatry 10:715-23. 2002.... - Verification of scale sub-domains in elderly patients with dementia: a confirmatory factor-analytic approachKari B Kastango
Department of Biostatistics, University of Pittsburgh, PA 15213, USA
Am J Geriatr Psychiatry 10:706-14. 2002..CONCLUSION: Authors advocate the use of a confirmatory factor-analytic approach to verify scale sub-domains in other, more widely used rating scales for patients with dementia... - Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniquesRobert R Bies
Western Psychiatric Institute and Clinic, University of Pittsburgh, PA 15213, USA
Am J Geriatr Psychiatry 10:696-705. 2002.... - Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patientsLalithKumar K Solai
Mental Health Intervention Research Center for the Study of Late Life Mood Disorders, University of Pittsburgh School of Medicine, Pennsylvania, USA
J Clin Psychopharmacol 22:481-6. 2002..CYP2D6 inhibition by paroxetine, which effectively converted 59% of patients to phenotypic PMs, may be especially relevant for elderly patients given their generally higher concentration of paroxetine... - Response speed and rate of remission in primary and specialty care of elderly patients with depressionLeslie Thomas
Intervention Research Center for Late-Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine, 3811 O'Hara Street, Pittsburgh, PA 15213, USA
Am J Geriatr Psychiatry 10:583-91. 2002..CONCLUSION: Notwithstanding these differences in speed and rate of symptom resolution, good treatment can work well in geriatric depression in the primary care sector... - Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depressionGwenn S Smith
Department of Psychiatry Research, Hillside Hospital of the North Shore Long Island Jewish Health System, 75 59 263rd Street, Glen Oaks, NY 11004, USA
Am J Geriatr Psychiatry 10:561-7. 2002.... - Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjectsGwenn S Smith
Department of Psychiatry Research, Hillside Hospital, Neuroscience Institute of the North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
Synapse 45:105-12. 2002..Future studies will evaluate how the acute metabolic response to citalopram relates to the metabolic response after chronic treatment in patients with geriatric depression... - Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjectsRae Ann Maxwell
Pharmacy Department, Western Psychiatric Institute and Clinic, VA Pittsburgh Health System, Pennsylvania, USA
J Geriatr Psychiatry Neurol 15:77-81. 2002..These results were unchanged when concentrations were corrected for total daily risperidone dose. Among elderly subjects, risperidone and 9-OH clearance do not decline with increasing age or declining CrCl... - A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depressionAdam B Burrows
Geriatrics Section, Boston University School of Medicine, 74 Fenwood Road, Boston, MA 02115, USA
Depress Anxiety 15:102-10. 2002..The study also illustrates the discordance between patient and caregiver ratings, and the difficulties in studying very elderly patients with mood disorders... - Treatment considerations for anxiety in the elderlyEric J Lenze
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
CNS Spectr 8:6-13. 2003..Overall, the research in late-life anxiety has not caught up to the literature in late-life depression and, for the most part, treatment recommendations must be extrapolated from studies in young adults... - The nature and determinants of neuropsychological functioning in late-life depressionMeryl A Butters
Department of Psychiatry, University of Pittsburgh Medical Center, PA, USA
Arch Gen Psychiatry 61:587-95. 2004..Further studies of neuropsychological functioning in remitted LLD patients are needed to parse episode-related and persistent factors and to relate them to underlying neural dysfunction... - Executive functioning, illness course, and relapse/recurrence in continuation and maintenance treatment of late-life depression: is there a relationship?Meryl A Butters
Intervention Research Center for Late Life Mood Disorders, Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh Medical Center, USA
Am J Geriatr Psychiatry 12:387-94. 2004..The authors tested the hypothesis that impaired executive functioning leads to high rates of relapse and recurrence in late-life depression... - A genetic algorithm-based, hybrid machine learning approach to model selectionRobert R Bies
Department of Pharmaceutical Sciences and Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
J Pharmacokinet Pharmacodyn 33:195-221. 2006..This includes structural, inter-individual random effects, covariate effects and residual error models using machine learning. This method is based on combinatorial optimization using genetic algorithm... - Maintenance treatment of major depression in old ageCharles F Reynolds
Advanced Center for Intervention and Services Research for Late Life Mood Disorders, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213, USA
N Engl J Med 354:1130-8. 2006..Elderly patients with major depression, including those having a first episode, are at high risk for recurrence of depression, disability, and death... - The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteersMatthew F Muldoon
Division of Clinical Pharmacology, Departments of Medicine and Epidemiology, University of Pittsburgh, 4015 O Hara Street, Pittsburgh, PA 15260, USA
J Clin Endocrinol Metab 91:718-21. 2006..The pathobiology of the metabolic syndrome remains unclear. The central nervous system is likely to be involved via regulation of eating, physical activity, blood pressure, and metabolism... - Development of a short form of the Severe Impairment BatteryJudith Saxton
Univ of Pittsburgh, Pittsburgh, PA, USA
Am J Geriatr Psychiatry 13:999-1005. 2005..The authors sought to develop a short form of the Severe Impairment Battery (SIB)... - Comorbid anxiety disorder in late life depression: association with memory decline over four yearsAlison K DeLuca
The Intervention Research Center for Late-Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Int J Geriatr Psychiatry 20:848-54. 2005..The data also suggest that anxiety disorders with an onset later in life may be associated with cognitive impairment, although further study is needed to confirm this finding... - Dextromethorphan-induced delirium and possible methadone interactionFrancis E Lotrich
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
Am J Geriatr Pharmacother 3:17-20. 2005..It is metabolized primarily by the cytochrome P450 (CYP) 2D6 isozyme. Methadone has been found to inhibit CYP2D6, indicating a potential for interaction with dextromethorphan... - Late-onset major depression: clinical and treatment-response variabilityHenry C Driscoll
Intervention Research Center for Late-Life Mood Disorders, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
Int J Geriatr Psychiatry 20:661-7. 2005..Further study of biological, neuropsychologic, and psychosocial correlates of late-onset, recurrent depression is needed... - Serum anticholinergic activity and cognition in patients with moderate-to-severe dementiaMarci L Chew
Western Psychiatric Institute and Clinic, 3811 O Hara St, Pittsburgh, PA 15213, USA
Am J Geriatr Psychiatry 13:535-8. 2005..The authors investigated the association between serum anticholinergic activity (SAA) and cognitive performance in a group of patients with moderate-to-severe dementia... - Accelerating symptom-reduction in late-life depression: a double-blind, randomized, placebo-controlled trial of sleep deprivationCharles F Reynolds
Intervention Research Center for Late Life Mood Disorders IRC LLMD, Univ of Pittsburgh School of Medicine, 3811 O Hara Street, E 113521, Pittsburgh, PA 15213, USA
Am J Geriatr Psychiatry 13:353-8. 2005..Authors tested the hypothesis that one night of total sleep deprivation (TSD) would accelerate antidepressant response to paroxetine, as compared with TSD+placebo (PBO) and paroxetine-alone, in late-life major depression... - Does education moderate neuropsychological impairment in late-life depression?Rishi K Bhalla
Intervention Research Center for the Study of Late Life Mood Disorders, Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, PA 15213, USA
Int J Geriatr Psychiatry 20:413-7. 2005..This study examined whether educational level influences the degree of neuropsychological impairment associated with late-life depression... - Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methodsPatricia R Houck
Department of Psychiatry, University of Pittsburgh, Western Psychiatric Institute and Clinic, UPMC Health System, Thomas Detre Hall, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
Psychiatry Res 129:209-15. 2004..No significant treatment differences were found. We conclude that attention to the missing-data mechanism should be an integral part in analysis of clinical trial data... - Utility of sparse concentration sampling for citalopram in elderly clinical trial subjectsRobert R Bies
Department of Psychiatry and Pharmaceutical Sciences, University of Pittsburgh, 805 Salk Hall, 3501 Terrace Street, Pittsburgh, PA 15213, USA
J Clin Pharmacol 44:1352-9. 2004..This is particularly valuable for populations such as the elderly, who are not typically available for pharmacokinetic studies... - Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influencesFrancis E Lotrich
Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
Psychopharmacology (Berl) 178:268-75. 2005..The neuroendocrine response to intravenous citalopram may provide an acute, functional, in vivo measure of the neural serotonin (5-HT) system... - Neuropathologic correlates of late-onset major depressionRobert A Sweet
Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Neuropsychopharmacology 29:2242-50. 2004..These preliminary findings suggest that AD is the predominant neuropathologic condition in LLMD subjects with dementia. Further assessment of the role of comorbid cerebrovascular disease and comorbid DLB is needed... - Effects of serotonin transporter promoter polymorphisms on serotonin functionGwenn S Smith
Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
Neuropsychopharmacology 29:2226-34. 2004.... - Intent-to-treat analysis for clinical trials: use of data collected after termination of treatment protocolSati Mazumdar
Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA 15261, USA
J Psychiatr Res 36:153-64. 2002..Statistical inference is based on bootstrap sampling procedures. We have illustrated this methodology using data from a drug trial comparing nortriptyline and paroxetine in the treatment of major depression in older patients...